Pfizer’s adjusted EPS of $0.77 surpassed estimates by $0.09 as non-COVID sales drove a 2.6% revenue increase.
Pfizer reported second-quarter adjusted earnings per share of $0.77, exceeding Wall Street expectations by $0.09. Revenue climbed 2.6% year over year, supported by stronger-than-anticipated demand for its non-COVID products.
The company raised its full-year revenue guidance following the results, which outperformed consensus estimates. Prior quarter earnings stood at $0.55, with revenue growth previously constrained by declining COVID-19 vaccine sales.
Shares showed limited movement in after-hours trading as investors digested the updated outlook.